PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE
申请人:Bristol-Myers Squibb Pharma Company
公开号:EP1196436A2
公开(公告)日:2002-04-17
FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF
申请人:Asahi Glass Company, Limited
公开号:EP2338935B1
公开(公告)日:2012-12-12
FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS
申请人:Nakano Takashi
公开号:US20110172336A1
公开(公告)日:2011-07-14
To provide a composition comprising a fluorocopolymer such as an ethylene/tetrafluoroethylene copolymer which can be produced at a relatively low temperature, and its production process.
A fluorocopolymer composition which comprises a fluorocopolymer such as an ethylene/tetrafluoroethylene copolymer and a fluorinated aromatic compound having a melting point of at most 230° C. and having a fluorine content in the compound of from 5 to 75 mass %, and is in a solution state at a temperature of at most the melting point of the fluorocopolymer, and a process for producing the fluorocopolymer composition, which comprises a step of dissolving the fluorocopolymer in a solvent containing the fluorinated aromatic compound at a temperature of at most the melting point of the fluorocopolymer.
US8952083B2
申请人:——
公开号:US8952083B2
公开(公告)日:2015-02-10
[EN] PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE<br/>[FR] INHIBITEURS DE LA PROTEASE DU VIRUS DE L'HEPATITE C A BASE D'ACIDE BORONIQUE PEPTIDE
申请人:DU PONT PHARM CO
公开号:WO2001002424A2
公开(公告)日:2001-01-11
The present invention relates generally to novel α-aminoboronic acids and corresponding peptide analogs represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R?1, R2, R3, Y1, Y2¿, and A are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of hepatitis C viral infections. The compounds of the invention are inhibitors of hepatitis C viral protease.